Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections
ACS Applied Materials & Interfaces · 10.05.2023 · 15 (18) · 21819-21829
DOI: 10.1021/acsami.3c00101 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 05.04.2023. Verfasst von Sampa Sarkar und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Australian Academy of Technology and Engineering, Rebecca L. Cooper Medical Research Foundation, Australian Research Council.
Abstract (Originalsprache)
Mycobacterium tuberculosis (MTB) causes the infectious disease tuberculosis (TB), responsible for more deaths than any other single infectious disease in history. Intracellular MTB are slow growing and difficult to target with traditional antitubercular drugs, leading to the emergence of multidrug resistance in TB infection, which is a major global public health issue. Recent advances in innovative lipid nanotechnologies for drug delivery have demonstrated promising outcomes for chronic infectious diseases but have not yet been tested as potential delivery systems for intracellular infections such as TB. The current study evaluates the potential of monoolein (MO)-based cationic cubosomes for the encapsulation and delivery of the first line antitubercular drug rifampicin (RIF) against an MTB-H37Ra in vitro culture model. In particular, we show that the use of cationic cubosomes as delivery vehicles reduced the minimum inhibitory concentration (MIC) of RIF by 2-fold against actively replicating MTB-H37Ra (compared to that of the free drug) and also shortened the lifecycle duration of axenic MTB-H37Ra from 5 to 3 days. The cubosome-mediated delivery was also found to be effective against intracellular MTB-H37Ra within THP-1 human macrophages, with a 2.8 log reduction in viability of the bacilli after 6 days incubation at the MIC. The killing time was also reduced from 8 to 6 days without distressing the host macrophages. Mechanistic studies on the uptake of RIF-loaded cationic cubosomes using total internal reflection fluorescence microscopy (TIRFM) demonstrated the capacity of these lipid particles to effectively target intracellular bacteria. Overall, these results demonstrate that cationic cubosomes are a potent delivery system for the antitubercular drug RIF for therapeutic management of TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia.
- School of Engineering, STEM College, RMIT University, Melbourne, Victoria 3001, Australia.
- The Commonwealth Scientific and Industrial Research Organisation, Manufacturing, Clayton, Victoria 3169, Australia.
ORCID-Profile: Sampa Sarkar, Brendan Dyett, Calum J Drummond, Charlotte E Conn
Förderung
- Australian Academy of Technology and Engineering
- Rebecca L. Cooper Medical Research Foundation
- Australian Research Council
- RMIT University
Zitieren
APA
Sarkar, S., Dyett, B., Lakic, B., Ball, A. S., Yeo, L. Y., White, J. F., Soni, S., Drummond, C. J., & Conn, C. E. (2023). Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections. ACS Applied Materials & Interfaces, 15(18), 21819-21829. https://doi.org/10.1021/acsami.3c00101
Vancouver
Sarkar S, Dyett B, Lakic B, Ball AS, Yeo LY, White JF, et al. Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections. ACS Applied Materials & Interfaces. 2023;15(18):21819-21829. doi:10.1021/acsami.3c00101
BibTeX
@article{Sarkar2023,
author = {Sarkar, Sampa and Dyett, Brendan and Lakic, Biserka and Ball, Andrew S and Yeo, Leslie Y and White, Jacinta F and Soni, Sarvesh and Drummond, Calum J and Conn, Charlotte E},
title = {Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections},
journal = {ACS Applied Materials & Interfaces},
year = {2023},
volume = {15},
number = {18},
pages = {21819--21829},
doi = {10.1021/acsami.3c00101}
}
EUVIMED